Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.
Balmaña, Judith
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. [electronic resource] - Cancer discovery Jun 2011 - 29-34 p. digital
Publication Type: Journal Article; Review
2159-8290
10.1158/2159-8274.CD-11-0048 doi
Antineoplastic Agents--therapeutic use
BRCA1 Protein--metabolism
BRCA2 Protein--metabolism
Breast Neoplasms--drug therapy
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Drug Evaluation, Preclinical
Humans
Molecular Targeted Therapy--methods
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerases--metabolism
Precision Medicine--methods
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. [electronic resource] - Cancer discovery Jun 2011 - 29-34 p. digital
Publication Type: Journal Article; Review
2159-8290
10.1158/2159-8274.CD-11-0048 doi
Antineoplastic Agents--therapeutic use
BRCA1 Protein--metabolism
BRCA2 Protein--metabolism
Breast Neoplasms--drug therapy
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Drug Evaluation, Preclinical
Humans
Molecular Targeted Therapy--methods
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerases--metabolism
Precision Medicine--methods